Search

Martina Doleshal

from Piedmont, CA
Age ~43
Get Report
Also known as:
Martina L
Phone and address:
535 Merritt Ave APT 5, Oakland, CA 94610
Related to:
Brandy Guntel Doleshal, 43Robert J Guntel, 70Candice A Guntel, 68Barbara H Doleshal, 77Candace GuntelZachary A Doleshal, 46Lindsay S Doleshal, 50Leslie L Doleshal, 80
Connected to:
Brad R Dolesh, 48Brian K Dolesh, 67Christopher F Dolesh, 45Katherine L Doleshal, 35Peggy A Dolet, 70Rebecca L Doletski, 56Christopher M Doleva, 42John E Doleva, 76Michael A Doley, 77Carrie L Dolezal, 65

Martina Doleshal Phones & Addresses

  • 535 Merritt Ave APT 5, Oakland, CA 94610
  • Piedmont, CA
  • San Marcos, TX
  • Madison, WI
  • Austin, TX
  • New Braunfels, TX
  • Smithville, TX
  • Huntsville, TX
  • Hays, TX

Resumes

Resumes

Martina Doleshal Photo 1

Owner And Principal Consultant

View page
Location:
Emeryville, CA
Industry:
Biotechnology
Work:
Novartis Vaccines and Diagnostics - Emeryville, CA since Apr 2012
Product/Marketing Manager, Global Marketing
Presidio Graduate School since 2010
Candidate MBA in Sustainable Management
Hologic Dec 2010 - Apr 2012
Product Manager
Asuragen Aug 2008 - Dec 2010
Product Manager
Asuragen Jan 2007 - Aug 2008
Scientist
Education:
Institute of Chemical Technology Prague 1999 - 2004
MS, Biochemistry and Biotechnology Alliant International University-San Francisco Bay
Skills:
Biotechnology
Strategy
Lifesciences
Molecular Biology
Product Development
Medical Devices
Dna
Life Sciences
Commercialization
Pharmaceutical Industry
Biochemistry
Molecular Diagnostics
R&D
Genomics
Validation
Product Launch
Fda
Product Marketing
Hardware Diagnostics
Laboratory
Genetics
Infectious Diseases
U.s. Food and Drug Administration
Oncology
Assay Development
Quality Assurance
Languages:
English
Czech
Certifications:
Pragmatic Marketing Certified Product Manager
Martina Doleshal Photo 2

Martina Doleshal

View page

Publications

Us Patents

Mirnas Differentially Expressed In Lymph Nodes From Cancer Patients

View page
US Patent:
20090263803, Oct 22, 2009
Filed:
Feb 9, 2009
Appl. No.:
12/368053
Inventors:
Sylvie Beaudenon - Austin TX, US
Laura Elizondo - Austin TX, US
Martina Doleshal - Austin TX, US
David Brown - Austin TX, US
Emmanuel Labourier - Austin TX, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain apsects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.

Mirnas Differentially Expressed In Lymph Nodes From Cancer Patients

View page
US Patent:
20140141423, May 22, 2014
Filed:
Oct 10, 2013
Appl. No.:
14/051354
Inventors:
- Austin TX, US
Laura Elizondo - Austin TX, US
Martina Doleshal - Austin TX, US
David Brown - Ausitn TX, US
Emmanuel Labourier - Austin TX, US
Assignee:
ASURAGEN, INC. - Austin TX
International Classification:
C12Q 1/68
US Classification:
435 611, 435 614, 435 612
Abstract:
The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain aspects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.
Control profile
Martina Doleshal from Piedmont, CA, age ~43 Get Report